Bioorthogonal transition metal catalysts (TMCs) transform therapeutically inactive molecules (pro-drugs) into active drug compounds. Inorganic nanoscaffolds protect and solubilize catalysts while offering a flexible design space for decoration with targeting elements and stimuli-responsive activity. These “drug factories” can activate pro-drugs in situ, localizing treatment to the disease site and minimizing off-target effects. Inorganic nanoscaffolds provide structurally diverse scaffolds for encapsulating TMCs. This ability to define the catalyst environment can be employed to enhance the stability and selectivity of the TMC, providing access to enzyme-like bioorthogonal processes. The use of inorganic nanomaterials as scaffolds TMCs and the use of these bioorthogonal nanozymes in vitro and in vivo applications will be discussed in this review.
Inorganic nanoparticles as scaffolds for bioorthogonal catalysts / H. Cristina-Maria, Z. Xianzhi, H. Rui, C. Yagiz Anil, S. Fedeli, R. Vincent M.. - In: ADVANCED DRUG DELIVERY REVIEWS. - ISSN 1872-8294. - 195:(2023 Apr), pp. 114730.1-114730.18. [10.1016/j.addr.2023.114730]
Inorganic nanoparticles as scaffolds for bioorthogonal catalysts
S. FedeliPenultimo
;
2023
Abstract
Bioorthogonal transition metal catalysts (TMCs) transform therapeutically inactive molecules (pro-drugs) into active drug compounds. Inorganic nanoscaffolds protect and solubilize catalysts while offering a flexible design space for decoration with targeting elements and stimuli-responsive activity. These “drug factories” can activate pro-drugs in situ, localizing treatment to the disease site and minimizing off-target effects. Inorganic nanoscaffolds provide structurally diverse scaffolds for encapsulating TMCs. This ability to define the catalyst environment can be employed to enhance the stability and selectivity of the TMC, providing access to enzyme-like bioorthogonal processes. The use of inorganic nanomaterials as scaffolds TMCs and the use of these bioorthogonal nanozymes in vitro and in vivo applications will be discussed in this review.| File | Dimensione | Formato | |
|---|---|---|---|
|
ADDR_2023_1-s2.0-S0169409X23000455-main.pdf
accesso riservato
Tipologia:
Publisher's version/PDF
Dimensione
5.82 MB
Formato
Adobe PDF
|
5.82 MB | Adobe PDF | Visualizza/Apri Richiedi una copia |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.




